May 8 (Reuters) - Arena Pharmaceuticals Inc:
* EXPECT TO INITIATE PHASE 3 STUDIES FOR RALINEPAG IN PULMONARY ARTERIAL HYPERTENSION IN SECOND HALF OF 2018
* ARENA PHARMACEUTICALS PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS
* Q1 REVENUE VIEW $2.8 MILLION -- THOMSON REUTERS I/B/E/S
* Q1 EARNINGS PER SHARE VIEW $-0.68 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:
